

Conflicts of interest: CUA Guideline on managing CRPC

Cite as: *Can Urol Assoc J* 2013;7(9-10):301. <http://dx.doi.org/10.5489/cuaj.1696>
Published online October 7, 2013.

Below are the Competing Interests for the authors of the CUA Guideline on Managing CRPC from the August 2013 issue.¹

Dr. Saad is an Advisory Board member for Amgen, Astellas, Janssen, Abbott, Sanofi and Bayer. He has also received research grants and honoraria from Amgen, Astellas, Janssen, Abbott, Sanofi and Bayer. Dr. Saad has also participated in clinical trials in the past 2 years for Amgen, Astellas, Janssen, Sanofi and Bayer. **Dr. Hotte** is an Advisory Board member for Pfizer, Janssen and Astellas. He has also received grants from Novartis, and honoraria from Janssen, Novartis and Astellas in the past 2 years. He has also participated in clinical trials for Oncogenex, Novartis, Astellas, GSK, Bayer, Boehringer Ingelheim and Exelixis in the past 2 years. **Dr. Catton** has received payment from Abbvie for preparation of educational materials. He has also received fellowship program support from Paladin and Abbvie and has received speaker fees from Astra-Zeneca. **Dr. Drachenberg** has attended Advisory Boards for Astellas and Janssen and has been a speaker for Amgen and Actavis (formerly Watson). He has also been an investigator in clinical trials run by Cancer Care Manitoba (CCMB). **Dr. Finelli** is Advisory Board member for Amgen, Astellas and Janssen. He has also received honoraria from Amgen, Astellas, Janssen, Paladin and Astra Zeneca. Dr. Finelli has also participated in clinical trials in the past 2 years for Amgen, Astellas, Janssen and Ferring. **Dr. Fleshner** is a member of the Advisory Board for Amgen, Janssen, Astellas and Eli Lilly. He has also received honoraria from Amgen, Janssen, Astellas and Eli Lilly in the past 2 years. He has also participated in clinical trials with the following companies in the past 2 years: Amgen, Janssen, Medivation, OICR, Prostate Cancer Canada. **Dr. Gleave** is a member of the Advisory Board for Oncogenex, AstraZeneca, Janssen and Astellas. He is also a member of the Speakers bureau for Janssen and Astellas and has received grants and honoraria from Amgen, Janssen, Astellas and AstraZeneca. He holds a patent for a product produced by Oncogenex and has investments in the company. He is participating in a clinical trial for OGS-011 and OGS-0427. **Dr. Kapoor** is a member of the Speakers bureau for Pfizer Oncology and Novartis Oncology. Dr. Kassouf is an Advisory Board member and a speaker for Amgen and Astellas. He has also received grants and honoraria from these companies. He is currently participating in unpaid clinical trials within the past 2 years. **Dr. Loblaw** is an Advisory Board member for AstraZeneca,

Sanofi, Janssen, Ferring, Paladin, Amgen and GE Healthcare. He has also participated in clinical trials for Sanofi and Paladin in the past 2 years. **Dr. North** is a member of the National Advisory Board for Astellas. He has also received honoraria from Astellas, Janssen and Sanofi. **Dr. Usmani** has received honoraria as an Advisory Board member from Amgen, Astellas, and Johnson and Johnson. **Dr. Chi** has received research grants from Astra Zeneca, Janssen and Oncogenex; and honoraria from Astellas, Bayer, Jansse, Millenium, Novartis and Sanofi in the past 2 years.

Also, please note the slightly modified figure illustrating the management of castration-resistant prostate cancer.




Fig. 1. Management of castration-resistant prostate cancer. PSADT: prostate-specific antigen doubling time.

Reference

1. Saad F, Hotte S, Catton C, et al. CUA-CUOG guidelines for the management of castration-resistant prostate cancer (CRPC): 2013 update. *Can Urol Assoc J* 2013;7:213-7. <http://dx.doi.org/10.5489/cuaj.1542>